Screener
Castle Biosciences CSTL Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Selling, general and administrative | 64,899 | 58,620 |
| Amortization of acquired intangible assets | 2,226 | 28,325 |
| Total operating expenses, net | 102,086 | 115,916 |
| Operating loss | (18,407) | (27,928) |
| Interest income | 2,545 | 3,099 |
| Net gains (losses) on equity securities | 2,022 | (1,425) |
| Interest expense | (134) | (17) |
| Other loss | (439) | — |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's operating income?
- Castle Biosciences (CSTL) reported operating income of -$18.41M in Q1 2026.
- How has Castle Biosciences's operating income changed year-over-year?
- Castle Biosciences's operating income increased by 34.1% year-over-year, from -$27.93M to -$18.41M.
- What is the long-term trend for Castle Biosciences's operating income?
- Over 4 years (2021 to 2025), Castle Biosciences's operating income has grown at a 1.7% compound annual growth rate (CAGR), from -$40.08M to -$42.81M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Castle Biosciences's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude